Scinai Immunotherapeutics Ltd. (SCNI)
USD 3.39
(-2.02%)
USD 3.39
(-2.02%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -9.38 Million | -7.26 Million | -7.86 Million | -233.04 Million | -280.79 Million | -199.28 Million |
| Net Income | -6.5 Million | -5.79 Million | -12.84 Million | -14.31 Million | -397.89 Million | -305.68 Million |
| Depreciation & Amortization | 514 Thousand | 562 Thousand | 776.1 Thousand | 7.82 Million | 5.99 Million | 905.97 Thousand |
| Deferred income taxes | - | - | -10.6 Thousand | -118.87 Thousand | -444.55 Thousand | 177.7 Thousand |
| Stock-based compensation | 1.13 Million | 1.6 Million | 886.01 Thousand | 9.46 Million | 13.42 Million | 905.97 Thousand |
| Change in working capital | -796 Thousand | 271 Thousand | 1.66 Million | -297.93 Million | 40.18 Million | 109.47 Million |
| Other non-cash items | 401 Thousand | -3.9 Million | -311.72 Thousand | 41.05 Million | 57.94 Million | -5.07 Million |
| Investing Cash Flow | -637 Thousand | -836 Thousand | -116.01 Thousand | -19.06 Million | -26.23 Million | -81.72 Million |
| Investments in PPE | -637 Thousand | -836 Thousand | -138.18 Thousand | -19.7 Million | -27.07 Million | -82.69 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | 22.17 Thousand | 632.91 Thousand | 838.1 Thousand | 965.2 Thousand |
| Financing Cash Flow | 1.08 Million | 6.77 Million | 21.78 Million | 44.06 Million | 310.51 Million | 293.81 Million |
| Debt repayment | - | - | -392.06 Thousand | -3.98 Million | -2.11 Million | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 139 Thousand | 932 Thousand | 22.17 Million | - | 256.05 Million | - |
| Other Financing Activities | 3925.24 | 5.84 Million | 21.37 Thousand | 48.04 Million | 56.57 Million | - |
| Accounts receivables | -1048.18 | 492.27 | 58.84 | -1760.59 | 1125.97 | - |
| Accounts payables | -150 Thousand | -175 Thousand | 398.17 Thousand | -48.81 Million | -13.34 Million | 50.52 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | -1286.73 | 446 Thousand | 1.26 Million | -249.11 Million | 53.52 Million | 58.95 Million |
| Cash at beginning of period | 14.21 Million | 17.51 Million | 3.02 Million | 232.81 Million | 276.51 Million | 248.73 Million |
| Cash at end of period | 5.01 Million | 14.21 Million | 17.36 Million | 30.26 Million | 264.06 Million | 264.41 Million |
| Capital Expenditure | -637 Thousand | -836 Thousand | -138.18 Thousand | -19.7 Million | -27.07 Million | -82.69 Million |
| Effect of forex changes on cash | -272 Thousand | -1.97 Million | 538.93 Thousand | 5.5 Million | -15.93 Million | 2.88 Million |
| Net cash flow / Change in cash | -9.2 Million | -3.3 Million | 14.33 Million | -202.55 Million | -12.44 Million | 15.68 Million |
| Free Cash Flow | -10.01 Million | -8.1 Million | -8 Million | -252.75 Million | -307.86 Million | -281.98 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -2.31 Million | -2.15 Million | -2.33 Million | -6.5 Million | 3.1 Million | -3.76 Million |
| Depreciation & Amortization | 494.19 Thousand | 156 Thousand | 84 Thousand | 514 Thousand | 145 Thousand | 147 Thousand |
| Deferred income taxes | - | - | - | - | -591 Thousand | -765 Thousand |
| Stock-based compensation | 142 Thousand | 191 Thousand | 453 Thousand | 1.13 Million | 234 Thousand | 200 Thousand |
| Change in working capital | -302.08 Thousand | 220 Thousand | 14 Thousand | -796 Thousand | -427 Thousand | -663 Thousand |
| Other non-cash items | 1.7 Million | 225 Thousand | 770 Thousand | 401 Thousand | -4.69 Million | 1.96 Million |
| Investing Cash Flow | -6009.87 | -2000.00 | -234 Thousand | -637 Thousand | -20 Thousand | -377 Thousand |
| Investments in PPE | -6009.87 | -2000.00 | -234 Thousand | -637 Thousand | -20 Thousand | -377 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 1977.79 | 1.42 Million | 10.66 Thousand | 1.08 Million | 1.08 Million | -3964.74 |
| Debt repayment | - | - | - | - | -2969.74 | -3964.74 |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | -3422.84 | - | - | - |
| Common Stock Issuance | 1977.79 | 1.43 Million | 10.66 Thousand | 139 Thousand | 1.07 Million | - |
| Other Financing Activities | 12 Thousand | 5242.35 | 3422.84 | 3925.24 | 4142.55 | - |
| Accounts receivables | -159.68 Thousand | 549.69 | -751.80 | -1048.18 | -343.31 | -85.25 |
| Accounts payables | -186.92 Thousand | 309 Thousand | -15 Thousand | -150 Thousand | -104 Thousand | -660 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 44.53 Thousand | -878.03 | 15.03 Thousand | -1286.73 | -323 Thousand | -3000.00 |
| Cash at beginning of period | 4.96 Million | 5.01 Million | 6.48 Million | 14.21 Million | 7.63 Million | 10.92 Million |
| Cash at end of period | 3.21 Million | 4.96 Million | 5.01 Million | 5.01 Million | 6.48 Million | 7.63 Million |
| Capital Expenditure | -6009.87 | -2000.00 | -234 Thousand | -637 Thousand | -20 Thousand | -377 Thousand |
| Effect of forex changes on cash | 121 Thousand | - | -14 Thousand | -272 Thousand | 7000.00 | -41 Thousand |
| Net cash flow / Change in cash | -1.75 Million | -44 Thousand | -1.47 Million | -9.2 Million | -1.14 Million | -3.29 Million |
| Free Cash Flow | -1.76 Million | -1.46 Million | -1.45 Million | -10.01 Million | -2.24 Million | -3.25 Million |
MNPR3
IMB
AST
SGIOF
JNEO
071050